LAVA Therapeutics (LVTX) announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. Most recently, Morris was the chief medical officer for Celyad Oncology (CYAD).
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LVTX:
- LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
- LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
- LAVA Therapeutics Announces Appointment of New Directors to the Board
- LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Lava Therapeutics announces updated data from Phase 1/2a trial of LAVA-051
